(Alliance News) - Fusion Antibodies PLC on Thursday celebrated the launch of a new commercial service from its research and development programme, designed to address mammalian cell surface expression.
Fusion is a Belfast-based contract research organisation, which provides a range of engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
Its new service, known as Mammalian Display, is designed to aid companies specialising in the identification of therapeutic antibodies from focussed libraries of sequences.
It is the first service to come from Fusion's ongoing OptiMAL programme, a mammalian antibody library intended to eliminate the need for platform switching in the discovery and preclinical optimisation of novel antibodies.
Fusion added that it is continuing to work on other aspects of the programme, particularly the development of its antibody library.
"We are delighted to be able to announce the successful development of the Mammalian Display technology, an output from our OptiMAL research programme. As our industry rapidly turns to find new ways to hasten the development of better bio-therapeutics to the clinic, we also anticipate deploying these capabilities to bring AI generated antibody sequences out of world class computer algorithms and into a world class antibody laboratory," said Chief Executive Officer Adrian Kinkaid.
Fusion Antibodies shares were trading 4.9% higher at 47.20 pence each in London on Thursday morning.
By Holly Beveridge; Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Fusion Antibody (FAB)